In Vitro Blood Testing and Hemolysis Analysis

The contract mandates the performance of in vitro blood testing to quantify plasma free hemoglobin and evaluate hemolysis levels using established and standardized protocols, with testing conducted using fresh human or animal blood samples. The work requires precise laboratory procedures aligned with industry best practices to ensure accurate and reproducible results, specifically focused on measuring pHb as an indicator of red blood cell breakdown. The project is designated as a total small business set-aside under SBA guidelines, with the NAICS code 541940 indicating it falls under other scientific and technical consulting services, and is issued under the FDA Office of Acquisitions and Grants Services within the Department of Health and Human Services. Proposals must be submitted by the deadline of July 20, 2026, and the work is to be performed under a subcontract arrangement with no specified place of performance, leaving flexibility for the contractor to execute the testing at an appropriate facility.